Published in the June 2022 issue of JAMA Ophthalmology, key findings further confirm Kemin FloraGLO as a safe and effective ingredient in slowing down the progression of Age-Related Macular Degeneration (AMD) after ten years of use and is a preferred choice of Lutein as part of the AREDS2 standard of care.
“We are pleased FloraGLO was the chosen lutein ingredient in the prestigious Age-Related Eye Disease Study 2 (AREDS2) by the National Institutes of Health’s National Eye Institute and couldn’t be happier the results of this study further confirm the many benefits of Kemin FloraGLO Lutein for eye health,” said Fred Khachik, Research Fellow at Kemin.
“FloraGLO Lutein has been the Gold Standard of Lutein in the marketplace for more than twenty-five years, with no reports of adverse events being reported. As the first branded lutein worldwide, FloraGLO has been the foundation of supplemental lutein research and serves as the basis for global safety standards and monographs for lutein.”
The goal of the NIH study was to assess the long-term risk of developing lung cancer and late age-related macular degeneration (AMD) and if there is a benefit to adding lutein/zeaxanthin to supplements.
The study reported data that combined with data from previous studies, suggests lutein/zeaxanthin should be preferred to beta carotene in AREDS2 formulation as it may be safer in terms of lung cancer risk and provide an incremental increase in prevention of progression to late AMD.
Kemin’s FloraGLO Lutein has been included in more than 100 human clinical research trials and publications. Key takeaways from study results include
- FloraGLO Lutein should be considered an important nutrient to maintain eye health
- FloraGLO Lutein is the same free-form version found in common fruits and vegetables and is easily absorbed by the body
- FloraGLO Lutein is proven to have high bioavailability and absorption – showing a 126% increase in plasma lutein at 14 hours
- FloraGLO Lutein in powder form is produced with DSM’s Actilease microencapsulation technology, a proprietary process that combines superior bioavailability, excellent stability, and very low extrusion losses, for lower overages and smaller tablets
- FloraGLO Lutein is GRAS from infants to adulthood.
Additionally, lutein has been shown to have additional benefits: for ‘beauty from within’ as well as brain health. FloraGLO Lutein has also been validated by clinical studies across all ages for improving cognitive function.
Kemin is dedicated to transforming lives and FloraGLO lutein has been helping maintain healthy eyes globally for over 25 years providing hope and benefits to consumers. “FloraGLO lutein, extracted from marigold flowers, is one of the safest, most trusted brands for all ages with over 100 human clinical publications,” said Dr Chris Nelson, President and CEO, Kemin Industries.
